1.	GP Extended Action Triptorelin Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A-97-52014-181, 2011-004213-16, NCT01673984
2.	Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial Phase: Phase III Type: Treatment Status: Active Age: No age specified Sponsor: Other Protocol IDs: 05-8-4, NCT00243646
3.	Phase III Randomized Study of Radical Prostatectomy With Versus Without Neoadjuvant Chemohormonal Therapy Comprising Docetaxel and Androgen-Deprivation Therapy With Leuprolide Acetate or Goserelin in Patients With High-Risk, Clinically Localized Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-90203, NCT00430183
4.	Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS) Phase: Phase III Type: Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: CDR0000571528, MRC-RADICALS-PR10, ISRCTN40814031, EUDRACT-2006-000205-34, EU-20767, PR13, NCT00541047
5.	Radiation Therapy With or Without Hormone Therapy in Treating Patients Who Have Undergone Surgery For Stage I, Stage II, or Stage III Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 80 and under Sponsor: Other Protocol IDs: CDR0000644215, EORTC-22043, EORTC-22043-30041, EU-20950, EUDRACT-2006-002772-17, EORTC-22043–30041, NCT00949962
6.	Phase III Randomized Study of Radiotherapy With or Without Short-Term Androgen-Deprivation Therapy in Patients With Intermediate-Risk Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-0815, RTOG 0815, NCT00936390
7.	Phase III Randomized Study of Androgen-Deprivation Therapy and High-Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Patients With Unfavorable Intermediate- or Favorable High-Risk Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-0924, RTOG-0924, NCT01368588
8.	Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GP/C/05/PRO, NCT01415960
9.	Hypo-fractionated Proton Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GU003-10, NCT01492972
10.	Phase III Study of Dose-Escalated Radiation Therapy and Standard Androgen-Deprivation Therapy (ADT) With a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Versus Dose-Escalated Radiation Therapy and Enhanced ADT With a LHRH Agonist and Steroid 17alpha-monooxygenase TAK-700 in Patients With High-Risk Prostate Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-1115, RTOG-1115, NCT01546987
11.	A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 20 to 85 Sponsor: Pharmaceutical / Industry Protocol IDs: TAP-144-SR(6M)IP/CPH-002, U1111-1128-6861, JapicCTI-121763, NCT01546623
12.	A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TAP-144-SR(6M)IP/CPH-202, JapicCTI-121762, U1111-1128-7039, NCT01546649
13.	Phase II Randomized Study of Adjuvant Endocrine Therapy With Versus Without Everolimus in Patients With High-Risk, Hormone Receptor-Positive, and HER2/neu-Negative Breast Cancer Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S1207, S1207, NCT01674140
14.	Intermittent Hormone Therapy in Men With Localized Prostate Cancer After Radiation Therapy or Radical Prostatectomy Phase: Phase II Type: Treatment Status: Active Age: over 21 Sponsor: Other Protocol IDs: 30296-A, L-8863, 06-2040-A-02, NCT00223665
15.	Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-190, NCT00776594
16.	Extended Endocrine Therapy for Premenopausal Women With Breast Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-280, NCT00903162
17.	Abiraterone Acetate, Prednisone, and Leuprolide Acetate or Goserelin Before and During Radiation Therapy in Treating Patients With Localized or Locally Advanced Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 7048, NCI-2009-01346, NCT01023061
18.	Phase II Randomized Study of Combined Androgen Deprivation Comprising Bicalutamide and Goserelin or Leuprolide Acetate With Versus Without Cixutumumab in Patients With Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S0925, S0925, NCT01120236
19.	Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR016945, COU-AA-203, NCT01088529
20.	Neoadjuvant Ipilimumab in Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2009-0135, NCT01194271
21.	Phase II Study of Abiraterone Acetate in Patients With Metastatic Prostate Cancer and a Sub-Optimal Prostate-Specific Antigen Following Initial Androgen-Deprivation Therapy Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S1014, S1014, NCT01309672
22.	Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation Phase: Phase II Type: Treatment Status: Active Age: 9 to 40 Sponsor: NCI Protocol IDs: 110136, 11-C-0136, NCT01338987
23.	The Role of Androgen Deprivation Treatment (ADT) in Docetaxe-Prednisolone Chemotherapy for Castrate-Resistant Prostatic Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UOSG-AMC-0803, NCT01487902
24.	Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MCC-16684, NCT01531205
25.	Study of MDV3100 as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MDV3100-07, NCT01547299